Elbasvir-Grazoprevir +/- Ribavirin in HCV GT 4
Pooled Analysis

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Study Features

**Design:** Pooled analysis of treatment naïve and treatment experienced adults with HCV genotype 4 who participated in phase 2 and 3 clinical trials involving treatment with elbasvir-grazoprevir for 12-16 weeks, with or without ribavirin.

**Entry Criteria**
- Chronic HCV genotype 4 (n = 155)
- 18 years or older
- Baseline HCV RNA ≥10,000 IU/mL
- Treatment naïve & Treatment experienced (prior PEG-INF-based failure)
- Persons with compensated cirrhosis permitted
- Persons with HIV infection permitted

**Primary End-Point:** SVR12

Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Results in Treatment Naive


Abbreviations: EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin
Elbasvir-Grazoprevir +/- RBV in HCV GT4
Pooled Analysis: Results in Treatment Experienced

Abbreviations: EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin

Pooled Analysis: Conclusions

**Conclusions:** “The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.”

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA-PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation is that of the author(s) and does not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.